1. Scrip
  2. >>Focus On Asia
  3. >>China

How One China State-Owned Group Became A Behemoth, Powered By COVID-19

But Will Size, Speed, Policy Support Matter More Than Innovation?

 
• By Brian Yang

Already producing a broader range of biologics than any biotech firm in the world, from antibodies via plasma products to testing assays to vaccines, the state-owned China National Biotec Group is becoming even bigger with policy support and one surprising helper: the coronavirus pandemic. But might it face challenges from innovators and foreign firms in a changing environment?

n95 face mask protection with china flag safety for novel Coronavirus 2019-nCov. wuhan corona virus disease coronavirus quarantine concept. Perfect for banner, background. Vector illustration
CHINA NATIONAL BIOTEC GROUP RISES AMID COVID-19 PANDEMIC • Source: Shutterstock

Sometime in early 2020, as reports of pneumonia cases of unknown origin started surfacing and circulating in Wuhan, a key central hub in China connecting the vast country’s capital Beijing in the north to Guangzhou in the south, a team of researchers took an overnight flight to the city of 11 million people.

That team was dispatched to the epicenter of the coronavirus pandemic by China National Biotec Group (CNBG), a state-owned...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.